



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 03-1039)

In re Application of:)	
)	
Norbert Müller)	
)	Examiner: TBA
Serial No.: 10/624,570)	
)	Art Unit: TBA
Filed: July 23, 2003)	
)	Confirmation No. TBA
For: Methods of Screening Schizophrenia)	

TRANSMITTAL LETTER


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

- In regard to the above identified application.
1. We are transmitting herewith the attached:
 - a) Supplemental Information Disclosure Statement with copies of 9 references
 - b) Supplemental IDS PTO Form-1449
 - c) Return Receipt Postcard
 2. With respect to fees:
 - a) No check is attached.
 - b) **General Authorization:** Please charge any underpayment or credit any overpayment our Deposit Account, No. 13-2490.
 3. **CERTIFICATE OF MAILING UNDER 37 CFR § 1.8:** The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 20 day of February, 2004.

Date: 2/20/04

Respectfully submitted,



Emily Miao
Registration No. 35,285



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 03-1039)

In re Application of:)
)
Norbert Müller)
) Examiner: TBA
Serial No.: 10/624,570)
) Art Unit: TBA
Filed: July 23, 2003)
) Confirmation No. TBA
For: Methods of Screening Schizophrenia)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In order to comply with discretionary regulations 37 CFR §§1.97 and 1.98, attached hereto is Form PTO-1449, copies¹ of the documents listed thereon. These documents contain information which the Examiner may consider to be important in deciding whether to allow the present application to issue as a patent.

1. Müller, Norbert et al., "Cellular and Humoral Immune System in Schizophrenia: A Conceptual Re-Evaluation," *The World Journal of Biological Psychiatry: The Official Journal of the World Federation of Societies of Biological Psychiatry*, Scotland, Vol. 1, No. 4, October 2000, pp. 173-179.
2. Schwarz, Markus J. et al., "Decreased Levels of Soluble Intercellular Adhesion Molecule-1 (sICAM-1) in Unmedicated and Medicated Schizophrenic Patients" *Biological Psychiatry*, United States, Vol. 47, No. 1, January 1, 2000, pp. 29-33.

¹To the extent that a document is listed and no copy of same is attached, then such document is not at the present time available to the undersigned or is available in the file of a parent application. If a listed document is not in the English language and an English translation is readily available, such translation is also attached; if translation is not attached it is not readily available to the undersigned. If a foreign language patent document is cited, and an English language equivalent is known to the undersigned, then such equivalent patent is also cited on the attached form along with the corresponding foreign language patent and a connecting arrow indicated therebetween; if no such English language equivalent is cited, then none is known to undersigned.

3. Vora, Devendra K. et al., "Polymorphisms and Linkage Analysis for ICAM-1 and the Selectin Gene Cluster", *Genomics*, United States, Vol. 21, No. 3, June 1994, pp. 473-477.
4. Salem, Jill E. et al., "The Role of Gender Differences in the Reduction of Etiologic Heterogeneity in Schizophrenia", *Clinical Psychology Review*, United States, Vol. 18, No. 7, November 1998, pp. 795-819.
5. Gately, Maurice K. et al., "The Interleukin-12/Interleukin-12-Receptor System: Role in Normal and Pathologic Immune Responses", *Annual Review of Immunology*, United States, Vol. 16, 1998, pp. 495-521.
6. Wakatsuki, Toru et al., "A Distinct mRNA Encoding a Soluble Form of ICAM-1 Molecule Expressed in Human Tissues", *Cell Adhesion and Communication*, Switzerland, Vol. 3, No. 4, November 1995, pp. 283-292.
7. Yamaguchi, Naoki et al., "Screening of SLC25A13 Mutations in Early and Late Onset Patients With Citrin Deficiency and in the Japanese Population: Identification of Two Novel Mutations and Establishment of Multiple DNA Diagnosis Methods for Nine Mutations", *Human Mutation*, United States, Vol. 19, No. 2, February 2002, pp. 122-130.
8. Joling, Piet et al., "Domain 5 of the Intercellular Adhesion Molecule-1 (ICAM-1) is Involved in Adhesion of B-Cells and Follicular Dendritic Cells", *Advances in Experimental Medicine and Biology*, United States, Vol. 355, 1994, pp. 131-135.
9. McGruffin, Peter et al., "Genetic Basis of Schizophrenia", *The Lancet*, England, Vol. 346, No. 8976, September 9, 1995, pp. 678-682.

In accordance with MPEP Sections 609 and 707.05(b), it is requested that each document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on Form PTO-1449. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

The present Disclosure Statement is being submitted in compliance with 37 CFR 1.56 insofar

insofar as an Examiner might consider any of the cited documents important in deciding whether to allow the application to issue as a patent, but the citation of each document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner, in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37 CFR 1.104(a) and 1.106(b) and, in the course of each search, will review for relevance every document cited on the attached form even if not initialed.

Early and favorable consideration is earnestly solicited.

Dated: _____


2/20/04

McDonnell Boehnen Hulbert & Berghoff
300 South Wacker Drive
Chicago, Illinois 60606
Telephone : (312) 913-0001
Facsimile: (312) 913-0002

Respectfully submitted,



Emily Miao
Registration No. 35,285

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 03-1039	Serial No. 10/624,570
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT 		Applicant: Norbert Müller	
		Filing Date: 07/23/2003	Group: TBA

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No

OTHER DOCUMENTS - Including Author, Title, Date, Pertinent Pages, Etc.

1.	Müller, Norbert et al., "Cellular and Humoral Immune System in Schizophrenia: A Conceptual Re-Evaluation," <i>The World Journal of Biological Psychiatry: The Official Journal of the World Federation of Societies of Biological Psychiatry</i> , Scotland, Vol. 1, No. 4, October 2000, pp. 173-179.
2.	Schwarz, Markus J. et al., "Decreased Levels of Soluble Intercellular Adhesion Molecule-1 (sICAM-1) in Unmedicated and Medicated Schizophrenic Patients" <i>Biological Psychiatry</i> , United States, Vol. 47, No. 1, January 1, 2000, pp. 29-33.
3.	Vora, Devendra K. et al., "Polymorphisms and Linkage Analysis for ICAM-1 and the Selectin Gene Cluster", <i>Genomics</i> , United States, Vol. 21, No. 3, June 1994, pp. 473-477.
4.	Salem, Jill E. et al., "The Role of Gender Differences in the Reduction of Etiologic Heterogeneity in Schizophrenia", <i>Clinical Psychology Review</i> , United States, Vol. 18, No. 7, November 1998, pp. 795-819.
5.	Gately, Maurice K. et al., "The Interleukin-12/Interleukin-12-Receptor System: Role in Normal and Pathologic Immune Responses, <i>Annual Review of Immunology</i> , United States, Vol. 16, 1998, pp. 495-521.

6.	Wakatsuki, Toru et al., "A Distinct mRNA Encoding a Soluble Form of ICAM-1 Molecule Expressed in Human Tissues", <i>Cell Adhesion and Communication</i> , Switzerland, Vol. 3, No. 4, November 1995, pp. 283-292.
7.	Yamaguchi, Naoki et al., "Screening of SLC25A13 Mutations in Early and Late Onset Patients With Citrin Deficiency and in the Japanese Population: Identification of Two Novel Mutations and Establishment of Multiple DNA Diagnosis Methods for Nine Mutations", <i>Human Mutation</i> , United States, Vol. 19, No. 2, February 2002, pp. 122-130.
8.	Joling, Piet et al., "Domain 5 of the Intercellular Adhesion Molecule-1 (ICAM-1) is Involved in Adhesion of B-Cells and Follicular Dendritic Cells", <i>Advances in Experimental Medicine and Biology</i> , United States, Vol. 355, 1994, pp. 131-135.
9.	McGruffin, Peter et al., "Genetic Basis of Schizophrenia", <i>The Lancet</i> , England, Vol. 346, No. 8976, September 9, 1995, pp. 678-682.

Examiner	Date Considered
-----------------	------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with any communication.